Where does Bright Peak Therapeutics's cap table come from?

Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Bright Peak Therapeutics's 2 recorded funding rounds.

Premier Alternatives

Bright Peak Therapeutics

Drug Discovery · Allschwil, Switzerland · Founded 2017 · Privately Held (backing)

Developer of cytokine therapeutics designed for the treatment of cancer and autoimmune diseases. Bright Peak Therapeutics is based in Allschwil, Switzerland and was founded in 2017. It has raised $244 million across 2 recorded rounds; the latest was a $90 million Series C in Jun 2024.

PMV mark · valuation

—

Oct 2026

Priced at

—

Total raised

$244.0M

Last round

Later Stage VC (Series C)

Jun 2024

Cap table — not yet on record

Bright Peak Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.

Pro members can request priority coverage with a 48-hour turnaround.

Pro

The prices on Bright Peak Therapeutics

·39 fund marks: filer, period, implied $/share

Pro · $99 a month

List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Or create a free account

Frequently asked about Bright Peak Therapeutics

Where does Bright Peak Therapeutics's cap table come from?: Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Bright Peak Therapeutics's 2 recorded funding rounds.